Clinical trial
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That…
NCT00191646 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191646 |
|---|---|
| Title | An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy |
| Official title | Phase III Randomized Trial of Induction Chemotherapy With Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients With Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube… |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms |
| Intervention type | Drug |
| Interventions | Gemcitabine, Paclitaxel, Carboplatin |
| Enrollment | 919 |
| Start date | Oct 1, 2002 |
| Primary completion | Aug 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 4, 2011 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: